Pure Global

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects - Trial NCT05677035

Access comprehensive clinical trial information for NCT05677035 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hyundai Pharm and is currently Completed. The study focuses on Contraception. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05677035
Phase 1
Completed
drug
Trial Details
ClinicalTrials.gov • NCT05677035
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects
A Single-center, Open-label, Parallel-group, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

Study Focus

Contraception

LINO-1713 1 tablet

Interventional

drug

Sponsor & Location

Hyundai Pharm

Seoul, South Korea

Timeline & Enrollment

Phase 1

Jan 11, 2022

Jun 15, 2022

20 participants

Primary Outcome

Pharmacokinetics parameters: Cmax,Pharmacokinetics parameters: Tmax

Summary

A single-center, open-label, parallel-group, phase 1 study to assess the safety,
 tolerability, pharmacokinetics, and pharmacodynamics of LINO-1713 in healthy Korean female
 subjects

ICD-10 Classifications

Contraceptive management
Oral contraceptives
Other contraceptive management
General counselling and advice on contraception
Personal history of contraception

Data Source

ClinicalTrials.gov

NCT05677035

Non-Device Trial